End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
16.11 CNY | +0.37% | +2.55% | +9.82% |
Apr. 29 | Zhejiang Huahai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 24 | Huahai Pharmaceutical Gets Approval to Market Busulfan Injection | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
Weaknesses
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+9.82% | 3.28B | C+ | ||
+26.47% | 664B | C+ | ||
+28.23% | 567B | B | ||
-6.33% | 354B | C+ | ||
+19.35% | 330B | B- | ||
+4.23% | 286B | C+ | ||
+13.53% | 234B | B+ | ||
+4.74% | 199B | B- | ||
-10.18% | 196B | A+ | ||
-4.04% | 148B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 600521 Stock
- Ratings Zhejiang Huahai Pharmaceutical Co., Ltd.